Clinical Trial Failures: The company's ongoing clinical trials for pipeline products may not achieve their primary endpoints, or new drug candidates may fail to demonstrate sufficient safety or efficacy, leading to abandonment or significant delays in development and commercialization.

Regulatory Approval Hurdles: Even if trials are successful, Ironwood's new drug candidates may not receive necessary regulatory approvals from health authorities like the FDA, or approvals may come with significant restrictions or delays, hindering market entry and revenue generation.

Intense Competition: Ironwood's marketed products, especially Linzess, face or may face significant competition from existing treatments, new market entrants, or the development of generic versions, potentially eroding market share and pricing power.